Showing results (271-280 of 406) with videos related to

Sort By:
Pageof 41
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|June 5, 2013
Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple MyelomaBritta Auel, Hartmut Goldschmidt, Thomas Geer, et al.
Oncoimmunology|October 6, 2018
The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myelomaMohamed H S Awwad, Katharina Kriegsmann, Julian Plaumann, et al.
Oncoimmunology|April 14, 2017
HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapyAnnika Nelde, Juliane Sarah Walz, Daniel Johannes Kowalewski, et al.
The Lancet. Oncology|October 26, 2010
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trialEckhard Thiel, Agnieszka Korfel, Peter Martus, et al.
Blood Cancer Journal|August 12, 2024
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigmCharlotte Pawlyn, Fredrik H Schjesvold, David A Cairns, et al.
The Lancet. Haematology|March 15, 2020
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trialMarc S Raab, Monika Engelhardt, Antje Blank, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 3, 2020
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTORMaria-Victoria Mateos, Pieter Sonneveld, Vania Hungria, et al.
The Lancet. Oncology|August 28, 2017
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, et al.
Blood Advances|November 9, 2020
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myelomaThierry Facon, Ruben Niesvizky, Maria-Victoria Mateos, et al.
Blood|April 28, 2006
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Barbara Wassmann, Heike Pfeifer, Nicola Goekbuget, et al.
Pageof 41